Loading
Life sciences · Journal article
Frontiers in Pharmacology · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Atrial fibrillation (AF) is associated with a significantly increased risk of thromboembolic complications, including ischaemic stroke. Despite the dominant role of oral anticoagulants, low-molecular-weight heparins (LMWHs) are still used in selected clinical scenarios. Aim The aim of this review was to summarise the current clinical role of LMWHs in atrial fibrillation, with particular emphasis on available evidence, practical limitations and selected complex clinical scenarios. Methods A review based on the analysis of available clinical trials, guidelines, and pharmacological data. Results Low-molecular-weight heparins are used primarily for bridging therapy and in situations where oral anticoagulation is temporarily contraindicated or not feasible. However, robust evidence supporting the long-term use of LMWHs for stroke prevention in atrial fibrillation remains limited. Conclusion Low-molecular-weight heparins should not be considered standard chronic therapy for atrial fibrillation. Further studies are needed to better define optimal anticoagulation strategies in patients with atrial fibrillation, particularly in complex clinical settings such as active cancer and thrombocytopenia.